← Eichor
Condition: Regorafenib Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Regorafenib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT06887218Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Phase 2 · 1 location(s) · Asan Medical Center · NCT05905887Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
Phase 2 · 10 location(s) · Centre Hospitalier Universitaire de Besancon · NCT06425133Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Phase 2/Phase 3 · 16 location(s) · Centre Hospitalier Universitaire de Besancon · NCT05462613GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06558773A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Tr
Phase 1/Phase 2 · 1 location(s) · Junjie Hang · NCT07040228Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Strom
Phase 2 · 1 location(s) · Jian Li · NCT07559864Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Pa
Phase 2 · 1 location(s) · Sergey Orlov, MD · NCT06949982Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
NA · 16 location(s) · Centre Leon Berard · NCT04055220Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
NA · 1 location(s) · The First People's Hospital of Changzhou · NCT06456515Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Tr
EARLY_Phase 1 · 1 location(s) · JIANG LONGWEI · NCT07343791ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
Phase 2 · 1 location(s) · University of Miami · NCT05366816KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06099821Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of Firs
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07501351Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05794971"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
Phase 2 · 1 location(s) · Beijing Friendship Hospital · NCT06829355Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
Phase 2 · 1 location(s) · Fudan University · NCT05057052Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With
Phase 2 · 1 location(s) · Fudan University · NCT07100392Regorafenib for Recurrent Meningioma (MIRAGE Trial)
Phase 2 · 17 location(s) · Istituto Oncologico Veneto IRCCS · NCT06275919Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT05917431Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorect
Phase 2 · 1 location(s) · Fudan University · NCT05963490Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
Phase 1/Phase 2 · 1 location(s) · Asan Medical Center · NCT07096609Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal
Phase 3 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06992648STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
Phase 2 · 1 location(s) · National Cancer Institute, Naples · NCT07213570Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
Phase 2 · 16 location(s) · Centre Leon Berard · NCT04698785The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and
Phase 2 · 1 location(s) · Shanghai Changzheng Hospital · NCT06930118A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With
Phase 2 · 1 location(s) · Meng Chao Hepatobiliary Hospital of Fujian Medical Universit · NCT06280105Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Phase 2 · 1 location(s) · Sarah K. Lynam MD · NCT05113368Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06911684GIST Oral Paclitaxel(Liporaxel)
Phase 2 · 1 location(s) · Asan Medical Center · NCT06326346
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.